Kalehua Capital Management LLC — 13F Holdings & Portfolio
CIK 2106181 · latest 13F-HR filed 2026-11-13
Kalehua Capital Management LLC manages $132.4M in 13F-reported U.S. long-equity assets across 22 reported positions as of its 2026-09-30 13F-HR filing. Its largest disclosed positions are MANE (13.34%), BOXX (13.28%), KRSA (10.70%). Quarter over quarter (versus its 2026-06-30 filing) the fund opened 10 new positions and exited 11; 1 existing position rose in reported value and 8 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-11-13
vs 2026-06-30
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
Portfolio map
Q3 26Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.
Sector mix
% of 13F valueSectors from each company's SIC code; funds and ETFs grouped separately.
Biggest buys and sells
Q2 26 → Q3 26Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.
13F assets and positions
4 quartersTotal reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.
Top positions over time
reported valueThe eight largest current positions, valued at each quarter end.
Concentration
top 10 = 80.7%Cumulative share of the portfolio held in the largest N positions.
As of the firm’s regulatory filing dated Mar 31, 2026.
| Name | Title / Status | Ownership | Type |
|---|---|---|---|
| CHANG, TAI-LI Control | SOLE MEMBER since May 2022 | 75% or more | Individual |
| Chang, Katie, Norman Control | CHIEF COMPLIANCE OFFICER since Jan 2025 | Less than 5% | Individual |
Ownership & leadership changes · 1 filing with changes since Feb 13, 2023
From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.
- AddedChang, Katie, Norman · CHIEF COMPLIANCE OFFICER · Less than 5% · control person
- ListedCHANG, TAI-LI · SOLE MEMBER · 75% or more · control person
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Trims
- X4 PHARMACEUTICALS INC-$6.6M -37.9%
- LEONABIO INC-$2.2M -61.2%
- UNIQURE NV-$1.7M -47.5%
- INFLARX NV-$1.2M -19.0%
- SURROZEN INC-$788.9K -7.9%
New Positions
- EA SERIES TRUST$17.6M
- KORSANA BIOSCIENCES INC$14.2M
- BETTERLIFE PHARMA INC$6.7M
- OBSIDIAN THERAPEUTICS INC$5.7M
- KORRO BIO, INC$4.7M
Exited Positions
- Compass Pathways Plc$11.6M
- Sionna Therapeutics Inc$8.7M
- Pharvaris NV$6.9M
- Karyopharm Therapeutics Inc$6.7M
- Cyclerion Therapeutics Inc$5.6M
Kalehua Capital Management LLC Holdings (2026-09-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | VERADERMICS INC | MANE | 922967104 | $17.7M | 13.34% | 145,695 | SH |
| 2 | EA SERIES TRUST | BOXX | 02072L565 | $17.6M | 13.28% | 148,471 | SH |
| 3 | KORSANA BIOSCIENCES INC | KRSA | 23255M303 | $14.2M | 10.70% | 442,653 | SH |
| 4 | X4 PHARMACEUTICALS INC | XFOR | 98420X202 | $10.8M | 8.15% | 3,722,840 | SH |
| 5 | ACLARIS THERAPEUTICS INC | ACRS | 00461U105 | $9.6M | 7.28% | 1,832,365 | SH |
| 6 | SURROZEN INC | SRZN | 86889P208 | $9.2M | 6.95% | 286,092 | SH |
| 7 | INHIBIKASE THERAPEUTICS INC | IKT | 45719W205 | $7.9M | 5.93% | 3,821,890 | SH |
| 8 | SEPTERNA INC | SEPN | 81734D104 | $7.6M | 5.75% | 194,544 | SH |
| 9 | BETTERLIFE PHARMA INC | BETRF | 08772P202 | $6.7M | 5.04% | 27,710,000 | SH |
| 10 | OBSIDIAN THERAPEUTICS INC | OBX | 67448A106 | $5.7M | 4.32% | 416,649 | SH |
| 11 | INFLARX NV | IFRX | N44821101 | $5.3M | 3.97% | 2,921,095 | SH |
| 12 | KORRO BIO, INC | KRRO | 500946108 | $4.7M | 3.54% | 473,595 | SH |
| 13 | ATTOVIA THERAPEUTICS INC | ATTO | 04987L102 | $3.4M | 2.59% | 200,000 | SH |
| 14 | DAMORA THERAPEUTICS INC | DMRA | G2646Y104 | $3.0M | 2.23% | 139,000 | SH |
| 15 | UNIQURE NV | QURE | N90064101 | $1.9M | 1.45% | 79,407 | SH |
| 16 | GOSSAMER BIO INC | GOSS | 38341P201 | $1.7M | 1.25% | 139,366 | SH |
| 17 | MILESTONE PHARMACEUTICALS IN | MIST | 59935V107 | $1.4M | 1.08% | 1,651,258 | SH |
| 18 | LEONABIO INC | LONA | 04746L203 | $1.4M | 1.06% | 393,701 | SH |
| 19 | ATRIUM THERAPEUTICS INC | RNA | 04965N104 | $932.8K | 0.70% | 112,652 | SH |
| 20 | INSTIL BIO INC | TIL | 45783C200 | $721.1K | 0.54% | 99,600 | SH |
| 21 | ATYR PHARMA INC | ATYR | 002120202 | $554.3K | 0.42% | 1,829,513 | SH |
| 22 | KAZIA THERAPEUTICS LTD | KZIA | 48669G303 | $537.4K | 0.41% | 56,013 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-09-30 | 2026-11-13 | $132.4M | 22 | 0002106181-26-000010 |
| 2026-06-30 | 2026-08-19 | $174.0M | 26 | 0002106181-26-000008 |
| 2026-06-30 | 2026-08-14 | $139.5M | 23 | 0002106181-26-000007 |
| 2026-03-31 | 2026-05-15 | $141.3M | 27 | 0002106181-26-000005 |
| 2026-03-31 | 2026-05-15 | $118.6M | 23 | 0002106181-26-000004 |
| 2025-12-31 | 2026-02-13 | $101.1M | 19 | 0002106181-26-000003 |
DALLAS, TX 75219